-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At present, there are not many effective treatments for recurrent Ph+ALL with T315I mutation; CD19 CAR T is a potential therapy for such patients.
These 7 patients with recurrent Ph+ALL with T315I mutation received CD19-specific CAR T cell therapy before or after allo-HSCT.
The results showed that of these 7 cases, 6 entered CR or CRp within 1 month after the first CAR T cell infusion.
In summary, the results of this study confirmed the efficacy of anti-CD19 CAR T cell therapy in the treatment of recurrent Ph+ALL with T315I mutation before and after allo-HSCT, and the therapy can be used in combination with Pranatinib.
Original source:
Fei Yang, et al.
ncbi.
nlm.
nih.
gov/31512942/" target="_blank" rel="noopener">Anti-CD19 chimeric antigen receptor T- cells induce durable remission in relapsed Philadelphia chromosome-positive ALL with T315I mutation
in this message